Medications to reduce breast cancer risk: a network meta-analysis of randomized controlled trials
This NMA confirms the efficacy of tamoxifen, raloxifene, and AIs, and identifies thiazolidinediones and third-generation SERMs as promising agents for breast cancer prevention, though not currently included in guidelines. These findings extend prior evidence and highlight the need for trials in premenopausal and racially diverse populations to address existing gaps.
Authors
- Chongliang Luo (ORCID: https://orcid.org/0000-0003-3682-9454)
- Minglu Liu
- Angela Hardi (ORCID: https://orcid.org/0000-0001-5693-8979)
- Ghazaleh Pourali (ORCID: https://orcid.org/0000-0001-8981-0947)
- Adetunji T. Toriola (ORCID: https://orcid.org/0000-0003-1079-2606)
- Supriya S Sherpa
Institutions
- Washington University in St. Louis (US)
Publication Details
- Journal
- Breast Cancer Research
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1186/s13058-025-02059-w
- Primary Topic
- Estrogen and related hormone effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- National Cancer Institute